Prognostic value of sequential measurements of amino‐terminal prohormone of B‐type natriuretic peptide in ambulatory heart failure patients
暂无分享,去创建一个
D. Moertl | A. Hammer | R. Berger | M. Huelsmann | R. Pacher
[1] C. Frampton,et al. Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure , 2006, Circulation.
[2] J. Cohn,et al. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. , 2006, The American journal of medicine.
[3] I. Olivotto,et al. Pre‐discharge B‐type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit , 2005, European journal of heart failure.
[4] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[5] A. Dobson,et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review , 2005, BMJ : British Medical Journal.
[6] M. Matsuzaki,et al. Significance of predischarge BNP on one-year outcome in decompensated heart failure--comparative study with echo-Doppler indexes. , 2005, Journal of cardiac failure.
[7] A. Ferreira,et al. N-Terminal–Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients , 2004, Circulation.
[8] Gabriel Thabut,et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. , 2004, Journal of the American College of Cardiology.
[9] A. Ferreira,et al. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. , 2004, International journal of cardiology.
[10] I. Squire,et al. Pre‐discharge, but not admission, levels of NT‐proBNP predict adverse prognosis following acute LVF , 2003, European journal of heart failure.
[11] M. Kurabayashi,et al. Brain natriuretic peptide facilitates severity classification of stable chronic heart failure with left ventricular dysfunction , 2003, Heart.
[12] Georg Heinze,et al. Comparing the importance of prognostic factors in Cox and logistic regression using SAS , 2003, Comput. Methods Programs Biomed..
[13] L. Fisher,et al. Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.
[14] M. Davies,et al. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations , 2002, BMJ : British Medical Journal.
[15] John A Spertus,et al. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. , 2002, Journal of the American College of Cardiology.
[16] K. Swedberg,et al. Guidelines for the diagnosis and treatment of chronic heart failure. , 2001, European heart journal.
[17] E. Hartter,et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. , 2001, Journal of the American College of Cardiology.
[18] S Capewell,et al. More ‘malignant’ than cancer? Five‐year survival following a first admission for heart failure , 2001, European journal of heart failure.
[19] L. Lenert,et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.
[20] M. Kinoshita,et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.
[21] P A Poole-Wilson,et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. , 1999, Circulation.
[22] K. Adams,et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.